Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12272262 | 1.00 | CYP24A1 (0.45) | CYP24A1MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL12272153 | 0.83 | CYP19A1 (0.48) | MAOAMAOBCYP19A1CYP11B2CYP26A1 | |
| SCHEMBL12457871 | 0.83 | CYP19A1 (0.48) | MAOAMAOBCYP19A1CYP11B2CYP26A1 | |
| SCHEMBL115638 | 0.80 | MAOA (0.58) | MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL7510392 | 0.78 | METAP1 (0.54) | MAOAMAOBCYP19A1CYP11B2CYP26A1 | |
| SCHEMBL1495967 | 0.77 | MAOA (0.58) | MAOAMAOB | |
| SCHEMBL29756894 | 0.77 | MAOA (0.58) | MAOAMAOB | |
| Sulfuric Acid SCHEMBL28143763 | 0.75 | MAOA (0.54) | MAOAMAOB | |
| SCHEMBL27323916 | 0.73 | MAOA (0.51) | MAOAMAOBMIF | |
| SCHEMBL1814542 | 0.71 | MIF (0.48) | CYP24A1CYP19A1CYP26A1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2685821-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | AbbVie Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20120238549-A1 | Nuclear Hormone Receptor Modulators | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012125797-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238549-A1 | Nuclear Hormone Receptor Modulators | NR5A1, NR5A2, NR3C2 | CYP24A1 106/4885MAOA 4366/4885MAOB 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.